TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a significant growth in short interest in December. As of December 29th, there was short interest totalling 55,882,896 shares, a growth of 4.4% from the December 15th total of 53,505,064 shares. Based on an average trading volume of 2,720,761 shares, the days-to-cover ratio is currently 20.5 days. Currently, 32.1% of the company’s stock are sold short.

Several equities analysts have recently commented on TXMD shares. Jefferies Group reiterated a “buy” rating and set a $15.00 target price on shares of TherapeuticsMD in a research note on Tuesday, September 26th. BidaskClub cut TherapeuticsMD from a “hold” rating to a “sell” rating in a research note on Wednesday, September 27th. Oppenheimer set a $10.00 target price on TherapeuticsMD and gave the company a “buy” rating in a research note on Monday, October 16th. Cowen reiterated an “outperform” rating and set a $16.00 target price (up from $13.00) on shares of TherapeuticsMD in a research note on Monday, November 6th. Finally, Cantor Fitzgerald reiterated a “buy” rating and set a $31.00 target price on shares of TherapeuticsMD in a research note on Wednesday, November 29th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. TherapeuticsMD currently has a consensus rating of “Buy” and an average price target of $14.50.

In other news, Director Tommy G. Thompson acquired 5,000 shares of the stock in a transaction on Friday, December 8th. The stock was bought at an average price of $6.21 per share, with a total value of $31,050.00. Following the completion of the transaction, the director now directly owns 3,555 shares of the company’s stock, valued at $22,076.55. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 23.92% of the stock is owned by company insiders.

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Principal Financial Group Inc. lifted its stake in TherapeuticsMD by 3.9% during the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock worth $114,000 after purchasing an additional 818 shares during the last quarter. Amalgamated Bank lifted its stake in TherapeuticsMD by 7.2% during the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock worth $104,000 after purchasing an additional 1,322 shares during the last quarter. Legal & General Group Plc lifted its stake in TherapeuticsMD by 6.5% during the second quarter. Legal & General Group Plc now owns 56,234 shares of the company’s stock worth $298,000 after purchasing an additional 3,441 shares during the last quarter. The Manufacturers Life Insurance Company lifted its stake in TherapeuticsMD by 3.4% during the second quarter. The Manufacturers Life Insurance Company now owns 123,580 shares of the company’s stock worth $651,000 after purchasing an additional 4,058 shares during the last quarter. Finally, Rhumbline Advisers lifted its stake in TherapeuticsMD by 3.5% during the second quarter. Rhumbline Advisers now owns 183,408 shares of the company’s stock worth $967,000 after purchasing an additional 6,232 shares during the last quarter. Hedge funds and other institutional investors own 73.69% of the company’s stock.

TherapeuticsMD (NASDAQ TXMD) opened at $6.15 on Monday. The company has a market capitalization of $1,330.00, a P/E ratio of -15.77 and a beta of 1.06. TherapeuticsMD has a one year low of $3.50 and a one year high of $8.30.

TherapeuticsMD (NASDAQ:TXMD) last released its earnings results on Monday, November 6th. The company reported ($0.07) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative return on equity of 65.16% and a negative net margin of 457.00%. The company had revenue of $4.42 million during the quarter, compared to analysts’ expectations of $5.36 million. During the same period in the prior year, the business posted ($0.13) EPS. The business’s revenue was down 19.7% on a year-over-year basis. analysts expect that TherapeuticsMD will post -0.37 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “TherapeuticsMD, Inc. (TXMD) Short Interest Up 4.4% in December” was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this story on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The correct version of this story can be accessed at https://theolympiareport.com/2018/01/15/therapeuticsmd-inc-txmd-short-interest-up-4-4-in-december.html.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.

Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.